TB-500 Fragment

TB-500 Fragment (Ac-LKKTETQ) is a synthetic heptapeptide corresponding to residues 17 through 23 of the endogenous 43-amino acid polypeptide thymosin beta-4, a ubiquitous intracellular G-actin sequestering protein that participates in cytoskeletal organization, cell migration, angiogenesis, and tissue repair. The fragment encompasses the central actin-binding domain of the parent molecule and is N-terminally acetylated to confer resistance to aminopeptidase degradation and to replicate the post-translational modification present on native thymosin beta-4. TB-500 Fragment has been the subject of substantial preclinical investigation since the early 2000s, when Philp et al. (2003) demonstrated that the synthetic LKKTETQ heptapeptide promoted dermal wound repair in db/db diabetic mice and in aged mice at efficacy levels comparable to the full-length thymosin beta-4 molecule, establishing the actin-binding domain as a sufficient pharmacophore for the tissue repair activity of the parent protein. The principal molecular mechanism of TB-500 Fragment is sequestration of G-actin monomers and modulation of actin polymerization dynamics, which promotes cell migration, endothelial tube formation, keratinocyte mobilization, and extracellular matrix remodeling. Downstream signaling involves activation of integrin-linked kinase (ILK), phosphorylation of Akt/protein kinase B, suppression of NF-kappaB-mediated proinflammatory cytokine release, and upregulation of matrix metalloproteinases that facilitate tissue remodeling during wound repair. The pharmacological profile of TB-500 Fragment is therefore characterized by four principal activities: promotion of angiogenesis, acceleration of wound healing, anti-inflammatory modulation, and facilitation of stem and progenitor cell migration. Preclinical evidence in rodent models has demonstrated accelerated dermal wound closure in diabetic and aged animals, cardioprotection following experimental myocardial infarction (demonstrated with the parent thymosin beta-4 molecule in the landmark Bock-Marquette et al. 2004 Nature study), promotion of hair follicle stem cell activation and hair growth (Philp et al. 2004), and anti-inflammatory activity through suppression of NF-kappaB nuclear translocation and reduction of TNF-alpha and IL-1-beta production. Human clinical data for the heptapeptide fragment itself are limited; the majority of clinical evidence derives from the full-length thymosin beta-4 molecule, which has been evaluated in Phase 2 and Phase 3 clinical trials for dry eye disease (RGN-259, RegeneRx Biopharmaceuticals) and in Phase 2 studies for neurotrophic keratopathy. The Phase 2 dry eye trial demonstrated statistically significant improvements in ocular discomfort (35.1 percent reduction) and corneal fluorescein staining (59.1 percent reduction) relative to vehicle control. The Phase 3 ARISE program in dry eye disease did not meet co-primary endpoints, though statistically significant improvement in ocular grittiness was observed. TB-500 Fragment is not approved by any regulatory authority for human therapeutic use. It is classified as a prohibited substance by the World Anti-Doping Agency under Sections S0 (Non-Approved Substances) and S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) and is prohibited in equine racing competition by multiple national racing authorities. Pharmacokinetic data from preclinical studies indicate a plasma elimination half-life of approximately 1.5 to 3 hours following subcutaneous administration, with subcutaneous bioavailability of approximately 60 to 80 percent relative to intravenous dosing; tissue-level effects persist substantially longer than plasma residence, consistent with the intracellular mechanism of action. The compound is supplied as a lyophilized powder and is reconstituted in bacteriostatic water for injection; it is stable at refrigerated conditions for up to 30 days after reconstitution. This monograph reviews the chemistry, synthesis, and structural characterization of TB-500 Fragment; the molecular pharmacology of actin sequestration, ILK activation, and NF-kappaB suppression; the pharmacokinetic profile; the preclinical evidence base across wound healing, cardiac repair, hair growth, and anti-inflammatory models; the clinical evidence derived from the parent thymosin beta-4 molecule; sourcing and quality verification; reconstitution and handling; stack interaction considerations; adverse event and safety signal assessment; and a comparative evaluation of five alternative tissue repair and regenerative peptides against TB-500 Fragment on five competency standards.